Evidence map›Paper›PMID 32403313›Full record

ReviewGenes2020

Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis.

Débora Lanznaster, Charlotte Veyrat-Durebex, Patrick Vourc'h, Christian R Andres, Hélène Blasco, Philippe Corcia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. BMP/TGF-β signaling as a modulator of neurodegeneration in ALS.Developmental dynamics : an official publication of the American Association of Anatomists · 2022
    Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Débora LanznasterUMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.ORCID 0000-0001-5911-3120
Charlotte Veyrat-DurebexUMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.
Patrick Vourc'hUMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.
Christian R AndresUMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.
Hélène BlascoUMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.
Philippe CorciaUMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics studies performed in patients with amyotrophic lateral sclerosis (ALS) reveal a set of distinct metabolites that can shed light on the pathological alterations taking place in each individual. Metabolites levels are influenced by disease status, and genetics play an important role both in familial and sporadic ALS cases. Metabolomics analysis helps to unravel the differential impact of the most common ALS-linked genetic mutations (as

Indexed as

MetabolomicsMutationAmyotrophic Lateral SclerosisAnimalsC9orf72 ProteinCells, CulturedDisease Models, AnimalDNA-Binding ProteinsGenome-Wide Association StudyHigh-Throughput Nucleotide SequencingHumansInduced Pluripotent Stem CellsPrecision MedicineRNA-Binding Protein FUSSuperoxide Dismutase-1C9orf72 ProteinC9orf72 protein, humanDNA-Binding ProteinsFUS protein, humanRNA-Binding Protein FUSSOD1 protein, humanSuperoxide Dismutase-1TARDBP protein, humanALSgeneticsiPSCmetabolomicspersonalized medicine

Identifiers

PMID32403313
PMCPMC7288444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.